Igal Louria Hayon - 29 Aug 2023 Form 4 Insider Report for Raphael Pharmaceutical Inc. (RAPH)

Role
Chief Technology Officer, Director
Signature
/s/ Igal Louria Hayon
Issuer symbol
RAPH
Transactions as of
29 Aug 2023
Net transactions value
+$9,990
Form type
4
Filing time
25 Mar 2024, 16:01:33 UTC
Previous filing
13 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RAPH Common Stock Exercise of in-the-money or at-the-money derivative security $9,990 +999,000 $0.0100* 999,000 29 Aug 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RAPH Warrants to purchase Common Stock Exercise of in-the-money or at-the-money derivative security -999,000 -100% 0 29 Aug 2023 Common Stock 999,000 $0.0100 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported is an exercise of warrants to purchase common stock. In accordance with General Instruction 4(c)(iii), the exercise price is reported under column 2 of this table.